Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

In The News

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Dec 9, 2022 SMH: ‘Waiting for your child to die is not an option’
Dec 8, 2022 Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research
Dec 5, 2022 Kazia Therapeutics talks positive pre-clinical data for EVT801
Dec 1, 2022 ASX opens to 7-month high after Powells positive news: Aus shares up 0.8%
Dec 1, 2022 Almost all sectors higher: Aus shares close up 1%
Nov 30, 2022 Kazia Therapeutics welcomes publication of positive pre-clinical data for EVT801 in peer-reviewed cancer research journal
Nov 1, 2022 ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon
Oct 28, 2022 Kazia Therapeutics’ (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models
Oct 28, 2022 Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources
Oct 28, 2022 US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement